Novartis AG
PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITOR
Last updated:
Abstract:
The present invention relates to a pharmaceutical combination comprising TNO155 and a KRASG12C inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in a SHP2 inhibitor combined with KRASG12C inhibition is beneficial in, for example, the treatment of cancers.
Status:
Application
Type:
Utility
Filling date:
10 Feb 2020
Issue date:
19 May 2022